LENSAR Inc (LNSR)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 4
Do Nothing: max overnight gap 18.21% exceeds 5%, so the protective stop cannot cover off-hours repricing, and avgDollarVolume20 is only about $1.29M versus the $5M liquidity floor.
Company overview
LENSAR, Inc. designs, develops, and markets laser systems for cataract treatment and corneal astigmatism management. Its products include the LENSAR Laser System and the ALLY Robotic Cataract Laser System, which assist surgeons in performing precise laser-assisted cataract surgeries. The company operates globally and is headquartered in Orlando, Florida.
Fundamental
fairLENSAR's revenue growth and gross margins are solid, but profitability and operating leverage remain uncertain.
Revenue growth has been solid over the last several years (~14% multi-year CAGR through FY2025) and gross margins are healthy, but the company remains loss-making on a full-year GAAP basis and reported earnings can be noisy due to one-time/non-cash items. Liquidity is adequate for now (cash $13.6M at 6/30/26, current ratio ~2.4) with an added $10M revolver disclosed post-quarter, yet as a micro-cap medical-device name it carries meaningful adoption, regulatory, and competitive risk.
Sentiment
goodMedia and sentiment are positive following recent earnings, highlighting profitability prospects and ALLY system demand.
Media tone is constructive following LENSAR’s Aug 13 Q2 results/business update (announced), with coverage emphasizing a return to profitability and stronger ALLY system demand; the 30–90d media baseline is too sparse/noisy for a confident sentiment-delta read. Legal/regulatory scans show no current investigations or material litigation overhang in the last 90 days.
Technical
goodThe stock shows a strong short-term breakout, but overbought indicators and low liquidity limit tradability.
LNSR has a strong short-term breakout profile: price is above the SMA20/SMA50 and EMA9/EMA21 stack, MACD is positive and above signal, and ADX is high at 49.19. The weak spots are that RSI/Williams are overbought, Friday closed below daily VWAP after the surge, and price still sits just under the SMA200.
You’re looking at 2026-08-16 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.